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The  proinﬂammatory  cytokine  tumor  necrosis  factor  (TNF)  orchestrates  complex  multicellular  processes
through  a wide  variety  of changes  that  it induces  in cell functions.  At various  stages  of  the  study  of
TNF,  attention  has  been  drawn  to  one of  three  different  modes  of  its  action.  The work  that  led to the
discovery of  this  cytokine  addressed  situations  in  which  it inﬂicts  massive  damage  to tissues  through  a
mode  of  action  that  appeared  to be unrestricted.  In the  years  that  followed,  attention  was  drawn  to  theaspases
ell death
hronic inﬂammation
ndotoxin tolerance
F-B
NF
existence  of  negative  feedback  mechanisms  that  do restrict  TNF  formation  and  function,  and  of reciprocal
mechanisms  for negatively  regulating  TNF-induced  gene  activation  and  of cell  death.  Most  recently,  the
discovery  of  the  critical  role  of  TNF  in  chronic  inﬂammatory  diseases  directed  attention  to  the  ability  of
TNF also  to act with  no  apparent  time  restriction.  Major  gaps  still  remain  in  our knowledge  of  the  cellular
and  molecular  basis  for  these  three  modes  of  TNF  action.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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. Introduction
Tumor necrosis factor (TNF), a cytokine generated by a variety
f different cells—most effectively by mononuclear phagocytes—in
esponse to a wide range of immune stimuli and stress conditions
1], is one of the major regulators of inﬂammation. Studies have
hown that this cytokine initiates and orchestrates a wide range of
ifferent functional changes in cells, thereby contributing to pheno-
ypically different phases in the inﬂammatory process. Throughout
ts history, research on TNF has periodically focused on differ-
nt forms of inﬂammation dictated by different modes through
hich this cytokine was found to coordinate cell function: a form
f inﬂammation where TNF formation and function are restricted
oth temporally and locally; an acute form that results in devastat-
ng destruction of tissues; and a chronic form in which the inﬂamed
issue responds continuously to TNF and also keeps on generating
t without any extraneous inducer (Fig. 1). This essay is a brief dis-
ourse on the state of our knowledge of the networks of cellular and
ignaling mechanisms that dictate these three different cybernetic
atterns.
. TNF and its receptors
TNF is generated by cells as a type II transmembrane protein [2]
hat can be proteolytically processed by TACE/ADAM17, a metallo-
roteinase of the adamalysin family [3], to yield a soluble form of
his cytokine. Both in its membrane-integrated and in its soluble
orms TNF assembles into homotrimers, and in both it can trigger
ignaling. It acts through binding to one of two single transmem-
rane receptors, TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1B), whose
ignaling activities differ.
Both TNF and its receptors belong to large families of related
igands and receptors, most of whose members serve immunoreg-
latory roles by activating a set of proximal signaling proteins that
he different members share. Although this essay focuses on TNF,
he modes of regulation described here also bear on the functioning
f other members of the TNF families.
The N-terminal part of the membrane-integrated form of TNF
xtends into the interior of the TNF-expressing cell. Similarly to
he intracellular domains of the TNF receptors, this intracellular
omain of the TNF molecule can be induced to associate with signal-
ng proteins. Binding of TNF to receptors on target cells thus results
ot only in ‘forward’ signaling by TNF through the receptors of those
ells, but also in ‘reverse’ signaling within the TNF-producing cells
4].
. Major signaling mechanisms activated by TNF and
acterial lipopolysaccharide
To accommodate the highly pleiotropic function of TNF, the
NF receptors orchestrate a complex set of molecular interactions
hat are dynamically modulated by multiple contextual cues. The
urrent knowledge of these signaling mechanisms and of the mech-
nisms that regulate them has been thoroughly overviewed in other
rticles [5–9]. Some of their principal features will be illustrated
ere through a few examples. Figs 1 and 2 present diagrammatic
llustrations of the modes of regulation of TNF signaling discussed
n this essay and of some of their contributory mechanisms.
The TNF receptors have no intrinsic enzymatic function. Sig-
aling is initiated by their imposed juxtaposition, which provides
ew scaffolds for recruitment of a limited set of adapter proteins
o the receptors through a few protein interaction motifs (such as
RAF-binding domains, the death domain, or the RIP homotypic
nteraction motif). Some of those initially recruited proteins (e.g.,
he TRAFs and the cIAPs) possess ubiquitin ligase activities. Theseental Biology 50 (2016) 105–114
recruited proteins conjugate polyubiquitin chains to the proteins
with which they interact, and the links between the ubiquitins in
these chains, rather than being located in the lysine corresponding
to the 48th residue in the ubiquitin chain (as occurs in the ubiq-
uitin chains that dictate proteasomal degradation), are kinds (such
as linkage in lysine 63, or linear linkage) that impose interactions
with signaling proteins. As a result, protein interactions are fostered
in the initiating complexes, and additional signaling proteins are
recruited and activated, through interaction of ubiquitin-binding
motifs in those proteins with these newly formed ubiquitin chains.
Several of the signaling pathways acting downstream of these
initiating complexes are comprised of protein kinase cascades and
serve mainly for gene activation. Thus, for example, the three-tiered
ERK, p38, and JNK MAP  kinase cascades activate transcription fac-
tors such as AP1. Such signaling pathways also activate dimeric
complexes of members of the NF-B transcription factor family by
phosphorylating inhibitory proteins of the IB family that associate
with these dimers. This phosphorylation targets the IB proteins
for proteasomal degradation. TNFR1 activates the ‘canonical’ NF-
B pathway, in which the protein kinase IKK2 mediates activation
of the NF-B dimer p65:p50. TNFR2 also triggers the ‘alternative’
NF-B pathway, in which the protein kinase IKK1 that acts down-
stream of the protein kinase NIK mediates generation of a RelB:52
NF-B complex.
Two other TNFR1-activated pathways serve to induce death. In
the ‘extrinsic cell-death pathway’ the proximal signaling protein is
caspase-8. This protease, through proteolytic processing and hence
activation of other members of the caspase cysteine protease fam-
ily, triggers apoptotic cell death. A recently discovered additional
pathway triggers programmed necrosis of cells (necroptosis). Its
core components are the protein kinases RIPK1 and RIPK3 and a
pseudokinase activated by RIPK3, called MLKL.
As mentioned in Section 2, when TNF is in its membrane-
integrated form, besides activating signaling in its target cells
through the two TNF receptors it also activates signaling within
the TNF-expressing cells. Molecules that interact with the TNF
molecule’s intracellular domain, as well as a free, cleaved form
of that intracellular domain, seem to contribute to this signaling
[4,10,11].
There is much similarity between the signaling mechanisms
activated by the TNF receptors and those activated by receptors
for pathogen components that induce TNF synthesis. Among the
latter is Toll-like receptor (TLR)4, to which bacterial endotoxin
(alias lipopolysaccharide, LPS) binds, and which is well known to
be capable of inducing TNF synthesis. This similarity is not coinci-
dental. TNF acts as an immune-defense mediator that alerts remote
cells to the pathogenic stimuli that induce its synthesis. TNF would
therefore indeed be expected to activate, within its target cells,
functional changes similar to those by which the cells have chosen
to respond initially to these pathogenic stimuli.
4. TNF as mediator of the acute tissue-damaging
inﬂammation observed in a tissue’s ‘hypersensitive’
response to pathogen components
4.1. Phenomena
TNF has been rediscovered several times over. On the ﬁrst two
occasions it was  discovered during explorations of mechanisms
underlying the swift, devastating damage that tissues undergo
in hypersensitive immune-response processes. One well-known
example of such destructive processes is the ‘Koch phenomenon’, a
necrotizing hypersensitive reaction unleashed by adaptive immune
mechanisms that are triggered by dual exposure to components
of Mycobacterium tuberculosis [12]. Other examples are the local
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Fig. 1. Differing patterns of inﬂammation orchestrated by TNF. (A−C) Hypersensitive response. Cellular activities contributing to this response, in the mouse experimental
model  in which TNF was  discovered [16]. (A and B) Priming. Initial exposure of the mouse to a pathogen (BCG, green arrow) primes the macrophages to yield enhanced
inducibility of TNF through effects of IFN- and other mediators generated by T cells and NK cells (magenta arrows). IFN- also primes cells to yield an enhanced response
to  TNF. (C) Elicitation. Re-exposure to a pathogen component (LPS) triggers massive generation of TNF in the primed macrophages (red arrows). Transfer of TNF-containing
serum  from primed to unprimed mice mediates selective hemorrhagic necrosis of tumors in the unprimed mice, hence the name ‘tumor necrosis factor’. However, in the
LPS-treated primed mice such selectivity was not observed. Because various target cells were also primed in them and also because of synergistic effects of TNF and LPS on
these  target cells (broken green arrow) the induction of TNF in these mice was  fatal. (D–F) Tolerance. (D) Exposure of cells to LPS or other pathogen components induces
generation of TNF, which in turn triggers signaling in various target cells (black arrows) and (in an autocrine manner) also in the TNF-producing cells. (E) Numerous negative
feedback mechanisms (blue arrows) are activated both in the TNF-producing cells and in the cells exposed to TNF. Some mechanisms are intracellular whereas others
operate  through effects of induced extracellular mediators (long blue arrow). (F) Owing to effects of the negative feedback mechanisms, re-exposure to a TNF-inducing
pathogen component or to TNF triggers considerably weakened TNF generation and TNF-induced signaling. (G–I) Chronic inﬂammation. Hypothetical sequence of events in
emergence of chronic inﬂammatory diseases, based on the ﬁndings that in experimental animals mere chronic expression of TNF incites chronic inﬂammatory diseases and
mere  inhibition of TNF function can yield prolonged remission associated with arrest of the chronic generation of TNF. (G and H) A hypothetical unknown agent (dark red
arrow)  incites chronic generation of TNF (red arrows), eliciting (I) a chronic type of response that perpetuates TNF generation. This generation apparently occurs through
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induced changes in lymphocytes and in NK cells, which in turn trigger the generatio
ycobacterium bacillus Calmette–Guérin; IFN-, interferon-; NK, natural killer; LP
he  reader is referred to the web version of this article.)
nd systemic Shwartzman reactions, which are mediated by the
nnate immune mechanisms triggered as a result of dual exposure
o bacterial components [13]. The ﬁrst two reports of TNF activity
escribed the cell-killing activity both of this cytokine and of the
losely related cytokine lymphotoxin in tracking mechanisms for
he massive tissue destruction initiated by lymphocyte activation,
s observed in the Koch phenomenon [14,15]. (One of these two
tudies employed an ex vivo model of the ‘delayed-type hypersen-
itivity’ that accounts for the Koch phenomenon [15].)
Seven years later TNF was rediscovered in a study in which a
ramatic tissue-destructive effect, seen in mice exposed to a prim-
ng effect of the Mycobacterium bacillus Calmette–Guérin (BCG) and
hen challenged with LPS, was recognized as a consequence of TNF
nduction [16]. The name ‘tumor necrosis factor’ was  intended toNF, mainly in macrophages, through direct cell–cell contact (dark red arrows). BCG,
polysaccharide. (For interpretation of the references to color in this ﬁgure legend,
highlight apparent tumor speciﬁcity in the hemorrhagic necrosis
that was seen to be induced in the particular experimental model
used. Subsequent studies clariﬁed, however, that the same kind
of damage is also inﬂicted on normal granulation tissue [17] and
that the selective nature of its elicitation is apparently dictated by
the particular type of integrin expressed by angiogenic endothelial
cells found in these tissues [18]. TNF was  found to inﬂict massive
damage in other ways as well [19]. The harmful potential of this
cytokine seems to be accounted for by its ability to induce in cells a
wide range of functional changes with destructive potential. These
include induction of cell ‘suicide’ [20], dissolution and growth arrest
of connective tissue, cartilage and bone [21,22], enhanced coagula-
tion of the serum that can result in clogging of blood vessels [23],
and others.
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Fig. 2. Diagrammatic representation of signaling mechanisms contributing to different modes of TNF action. The diagram presents a highly simpliﬁed illustration of the
major  signaling pathways activated by TNF and some examples of their modulation in the different modes of TNF action discussed in this essay. Hexagons represent protein
kinases and protein kinase analogs; quadrilaterals represent cysteine proteases of the caspase family. (A) Examples of the kinds of negative feedback mechanisms that restrict
the  proinﬂammatory function of TNF. (1) Receptor shedding. (2) Induced synthesis of proteins that dissociate the proximal signaling complexes. (3) Induced synthesis of
ubiquitin chain-modifying enzymes. (4) Inhibitory self-phosphorylation of protein kinases. (5) Induced synthesis of proteins and of lncRNAs that bind transcription factors
and  arrest their function. (6) Induced synthesis of proteins that arrest activation of genes by associating with their DNA or chromatin components. (7) Induced synthesis of
phosphatases that dephosphorylate MAP  kinases. (B) Examples of mechanisms believed to contribute to a chronic response to TNF. (1) Soluble TNF receptors accumulating
at  sites of chronic inﬂammation might act as buffering agents, extending the duration of TNF action. (2) Triggering of TNFR1 induces TNFR2 synthesis. (3) TNFR2 signals for
activation of the alternative NF-B pathway, which may  facilitate a chronic response to TNF in two ways. First, by cleaving induced p100 and p105 molecules it can arrest
their  inhibitory effects on the function of canonical NF-B complexes. (4) Secondly, the activities of some of the genes that were activated by the canonical pathway can be
maintained by RelB:p52 dimers generated by the alternative pathway, while being unaffected by inhibitors of the canonical NF-B pathway. (5) Prolonged stimulation by TNF
yields  generation of IFN-. Stat1-activated by IFN-, acting together with TNF-induced NF-B, constitutively turns on various ‘interferon signature’ genes characteristic of
chronic  inﬂammation. (C and D) Mechanisms contributing to reciprocal negative regulation of gene activation and cell-death induction by TNF. (C) Mechanisms contributing
to  arrest of death induction upon induction of gene activation. (1) Proteins upregulated via NF-B activation block the assembly of signaling complexes that initiate both
the  extrinsic caspase-mediated cell-death pathway to apoptosis and the kinase cascade leading to necroptosis. (2) Other NF-B-activated genes block downstream events
in  the extrinsic cell-death pathway. (3 and 4) Chronic activation of JNK, which enhances death induction by TNF, is also withheld by NF-B activated genes. (D) Mechanisms
contributing to the arrest of signaling for gene activation upon induction of apoptotic cell death. (1) Whereas the activation of NF-B and some other signaling pathways
contributing to TNF-induced inﬂammation is mediated by signaling complexes that associate with the TNF receptor shortly after TNF binds to it (while the receptor is still
expressed on the cell surface), signaling for cell death is initiated by cytoplasmic complexes that are generated only later, after uptake of the TNF receptors into the cell. This
time  gap allows the proinﬂammatory and anti-death signaling pathways to prevail in the absence of contextual cues that would arrest the latter mechanisms. (2) Caspases
activated via the extrinsic cell-death pathway cleave proteins that participate in initiation of the signaling pathways that lead to NF-B activation. Besides abolishing the
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aignaling activity of these proteins, cleavage of some of the proteins also yields fra
hat  initiate inﬂammation are also cleaved and are thus inactivated by caspases. (4)
on-coding; TNFR1 and TNFR2, TNF receptor 1 and 2.
.2. Mechanisms and physiological relevance: fragmentary
nowledge and open questions
In view of the disappointing results of the clinical studies
rompted by the tissue-destructive anti-cancer effects of TNF [24]
nd by its contribution to acute inﬂammatory conditions [25] in
xperimental animal models, research interest in hypersensitive
esponses involving TNF declined, leaving many open questions
bout their mechanisms. What we did manage to learn until thens inhibitory to signaling. (3) Some of the distal signaling proteins in the pathways
ic activation of JNK enhances death induction by TNF. IFN-, interferon ; lnc, long
was that when TNF elicits hypersensitive responses it does so
in cooperation with other speciﬁc inducing agents such as inter-
feron gamma  (IFN ) [26] (Fig. 1a) whose production can occur
secondarily to that of IL-12 [27]. Other such agents are IL-1 [28]
and TLR ligands such as LPS [29]. While there is quite detailed
knowledge of various mechanisms that contribute to the priming
effects of IFN  [30–32], very little is known of the mechanisms
by which TNF function synergizes with those of IL-1 and of TLR
ligands.
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As described in Section 5, both the induction of TNF and
ts cellular effects are restricted by multiple negative feedback
echanisms. IFN-, besides enhancing cell responsiveness to TNF
nducers and TNF effects—for example, by upregulation of the
NF receptors [33]—also counteracts the inhibitory effects of these
ntagonizing mechanisms. As an example, IFN- reverses the gene
emodeling arrest dictated by negative feedback mechanisms [34].
Our knowledge of the exact effector mechanisms by which TNF
licits its dramatic tissue-destructive effect is even more fragmen-
ary. The direct cell-killing activity (by which TNF was detected
n the early studies that led to its discovery [14,15]) seems to
ontribute little to the tissue-damaging effects observed in the
ubsequent study in which its name was coined [16]. The evi-
ence suggests that in the latter case the damage derives from
he coordinated action of several different effector immune func-
ions [17,18,35–37]. The details of this coordination, however, are
nclear. It is not known exactly how these various activities are
rchestrated by TNF to yield dramatic rapid destruction of tissue,
r to what extent the various distinct phenomena of massive tissue
estruction that prompted the research leading to the discovery of
NF involve the same or different cellular activities and the same
ode of coordinating them.
. Restricted TNF formation and function: lessons form
ndotoxin tolerance
.1. Phenomena
It has long been known that whereas in some situations expo-
ure to immune stimuli primes the immune system to respond
ore vigorously upon second stimulation, in other situations
uch pre-exposure has the opposite effect, resulting in decreased
esponsiveness. Such desensitization was ﬁrst noticed in studies
f activation of adaptive immunity by antigens [38,39] and later it
as also observed when activation of innate immune responses by
acterial toxins was assessed. The latter phenomenon, ‘endotoxin
olerance’, was found to affect proinﬂammatory effects of the tox-
ns while not affecting or even enhancing other induced changes,
ncluding some leading to suppression of inﬂammation [40].
The discovery of TNF and its role in mediating many of the
roinﬂammatory functions of LPS [19,41,42] shed new light on the
echanisms of endotoxin tolerance. TNF generation was found to
e among the LPS effects that were most effectively suppressed
fter pre-exposure to pathogen components [43–45]. Furthermore,
NF itself was found to render cells unresponsive to various LPS
ffects including TNF induction. Evidence was presented to sug-
est that TNF can also induce in cells ‘tolerance’ to some of its own
ffects [45] (Fig. 1b). The ability of both LPS and TNF to suppress
he response to subsequently applied inducers of proinﬂammatory
unctions was also shown to affect innate immune responses to
arious other potentially damaging challenges, such as ischemic
eperfusion [46–48] and hyperthermia [49].
.2. Mechanisms
.2.1. Intracellular mechanisms restricting induction and
roinﬂammatory functions of TNF
The complexity of signaling mechanisms acting downstream of
he TNF receptors is mirrored by a similar complexity of feedback
echanisms controlling those functions. A complex set of mecha-
isms, similar to those that regulate TNF function, also controls the
ignalling by receptors for pathogen components such as LPS that
nduce TNF formation. These mechanisms have been listed in great
etail elsewhere (e.g. [50–53]). A few examples are provided here
o illustrate the kinds of mechanisms involved (Fig. 2a).ental Biology 50 (2016) 105–114 109
Some of the feedback mechanisms are exerted by pre-existing
proteins, enabling rapid arrest, while others are mediated by pro-
teins newly generated upon gene activation by TNF receptors and
the LPS receptor TLR4. Binding of ligands by the receptors triggers
downregulation of the latter, which occurs both via their uptake
into the cell and by their proteolytic cleavage [54–59]. Mutational
ablation of the proteolytic cleavage of TNFR1 was convincingly
shown to facilitate inﬂammation [60].
Further downstream, assembly of the proximal signaling com-
plexes is downregulated by induced synthesis of enzymes that
reverse the polyubiquitin-chain generation fostering this assem-
bly. One example of such an enzyme is CYLD, a deubiquitinase that
speciﬁcally disassembles K63-linked polyubiquitin links. Another
is A20, a multifunctional protein that besides catalyzing deubiqiti-
nation can also block the function of polyubiquitin chains merely
by binding to them, and can catalyze the generation of K48-linked
polyubiquitin chains that dictate protein degradation [61]. TLR4
induces functional arrest of its proximal signaling complexes via
induction of proteins such as SOCS1, IRAK-M and SHIP-1, which
displace crucial components of these complexes [51,53]. SODD, a
protein that seems to bind speciﬁcally to TNFR1, was suggested
to serve a similar inhibitory role in restricting signaling activation
by this receptor, except that SODD seems to act constitutively to
arrest signaling, and that TNF was  claimed to transiently abate its
inhibitory effect [62].
Of the various signaling mechanisms activated by LPS and
TNF, the pathways leading to NF-B activation play a particu-
larly important role in the induction of genes that participate
in the inﬂammatory process. These pathways can be temporally
restricted at multiple mechanistic levels. Self-phosphorylation of
IKK2 [63] and phosphorylation of NIK by IKK1 once these kinases
have been activated [64] serve to downregulate their kinase
activities in a protein synthesis-independent manner. The NF-B
p65:p50 dimers, after mediating gene activation, are destroyed
through effects of ubiquitin ligases such as PLIM2 [65] or of proteins
(e.g., MURR1/COMMD1) that coordinate the function of such ligases
[66–68]. NF-B function is also arrested by induced inhibitory pro-
teins of the IB family [69–74]. Moreover, accessibility of NF-B
regulated genes to the activated NF-B proteins is decreased by
induced association of these genes with dimers of the p50 or p52
NF-B proteins that have transcriptional inhibitory effects [75,76].
Both the activation of transcription by LPS and its activation by
TNF require chromatin remodeling. The tolerization by both agents
to such activation is reﬂected in speciﬁc arrest of the remodeling
of genes that mediate inﬂammation [77]. In the case of TNF (but
not of LPS), induction of this arrest in macrophages depends on the
function of the kinase GSK3 [78].
The stimulatory effect of other signaling pathways through
which TNF stimulates gene activation, such as the ERK- and p38
MAP-kinase cascades, can also be suppressed by their prior expo-
sure to TNF and LPS. This occurs, for example, by activation of the
genes for phosphatases that dephosphorylate and thus reverse the
activation of the kinases that participate in these pathways. Of par-
ticular importance for the emergence of endotoxin tolerance is the
induction by p38-kinase of the gene encoding a phosphatase (MAP
kinase phosphatase-1) that dephosphorylates this kinase, thereby
inactivating it. One of the consequences of p38 activation is inhibi-
tion of the function of proteins that destabilize various short-living
mRNAs, including that of TNF. Arrest of the function of p38 kinase
therefore results in post-transcriptional arrest of TNF synthesis
[7,79].
Genes activated by LPS or TNF are also found to be down-
regulated by micro-RNAs induced upon pre-exposure to these
agents. These micro-RNAs associate with the transcripts encoded
by these genes and enhance their degradation or block their
translation [80,81]. Recent evidence indicates that certain induced
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ong non-coding RNAs (lncRNAs) also contribute to endotoxin
olerance. One such lncRNA, called ‘Lethe’, whose synthesis is
nhanced by TNF, binds to the NF-B p65/p50 dimer and thus
locks activation of the canonical NF-B pathway [82].
Reverse signaling by cell-surface TNF provides another level of
ontrol allowing activities of the TNF-producing cells, including the
xpression of TNF, to be adjusted to the effectiveness of TNF func-
ion. One of the main functions of the ‘reverse signals’ emanating
rom TNF upon its binding to its receptors appears to be inhibition
f TNF synthesis [4,83,84].
.2.2. Reciprocal negative regulation of gene-activation and
ell-death-induction pathways
Among the numerous functional changes induced in cells by
NF and TNF-inducing agents, the induction of cell death is excep-
ional not only in its functional connotation but also in the mode
f its restriction. This mode of restriction was noticed before the
estriction of any other function of TNF was detected. In a study of
ybrids of cells with differing grades of sensitivity to TNF-induced
eath, cellular resistance to death was found to be a dominant fea-
ure, suggesting the existence of some ‘anti TNF-induced death
echanisms’ in cells [85]. Treatment of cells with inhibitors of
rotein synthesis has long been known to sensitize cells to TNF
ytotoxicity. Conversely, their treatment with TNF or IL-1 under
onditions allowing protein synthesis enhances cellular resistance
o TNF-induced death [20,86,87]. These ﬁndings indicated, ﬁrstly,
hat TNF signals for cell death through pathway(s) that are indepen-
ent of protein synthesis. Secondly, unlike the various phenomena
escribed in Section 5.2.1, where a signaling pathway is restricted
y activities and proteins operating within the same pathway,
he TNF-activated cell-death pathways are restricted by other
athways. Although the cell-death pathways are themselves inde-
endent of protein synthesis, they are inhibited by TNF-activated
athways that do signal for protein induction.
Indeed, neither the function of the extrinsic apoptotic path-
ay nor necroptosis requires protein synthesis and both can be
locked by certain proteins synthesized as a consequence of the
NF-mediated activation of pathways that lead to NF-B activation.
oth the extrinsic cell-death pathway and necroptosis are blocked
y the NF-B-induced protein cFLIP(L) [88–90]. NF-B-induced
roteins also act to restrict the duration of JNK activation by TNF,
hereby preventing the strong enhancement of TNF-induced apop-
otic death by chronically activated JNK that is apparently exerted
hrough functional arrest of various anti-death proteins [91].
An additional mechanism by which NF-B activation restricts
he extrinsic cell-death pathway is through S-nitrosylation of
aspases subsequently to NF-B-mediated induction of NO syn-
hetase [92]. Several other anti-apoptotic mechanisms acting
urther downstream in the extrinsic pathway [93] are also con-
rolled by NF-B (Fig. 2c). Some proximal events in the TNF-induced
athway that leads to NF-B activation are themselves inhibitory
o proximal events in cell-death induction [94–96].
Conversely, caspase activation in the induction of apoptotic cell
eath arrests the activation of NF-B through cleavage of signal-
ng proteins (such as RIPK1) and generation of their inhibitory
ragments [97–99] (Fig. 2d). Such reciprocal negative regulation,
ediated via the inhibitory effects of proximal signaling enzymes,
s also observed between the extrinsic apoptotic and the necrop-
otic death pathways [89,100,101].
NF-B is activated by TNFR1 shortly after its stimulation, before
NFR1 is taken up and before the TNF-induced activation of JNK
eaches the duration at which it enhances death induction. In con-
rast, induction of the extrinsic cell-death pathway and necroptosis
re triggered only after uptake of the receptor and generation of
ytosolic signaling complexes [102]. Death is therefore normallyental Biology 50 (2016) 105–114
induced only when speciﬁc contextual cues arrest the anti-death
mechanisms associated with the NF-B pathway.
Induction of hepatocyte death in mice in vivo results in mas-
sive damage to the liver and consequently in death of the mice.
Such death is the basis for a test that is widely used to assess the
effectiveness of LPS and TNF functioning in vivo [103]. As with
the death-inducing effect of TNF ex vivo, this deadly effect in vivo
depends on arrest of the synthesis of NF-B-activated genes, and
as in the ex vivo effect it can be withheld by pre-exposure to TNF
or IL-1 [104,105].
The relevance of the cross-regulation of gene activation and
cell death induction for the control of inﬂammation depends on
the particular mode of death induced in the particular situation.
Necroptosis and chronic activation of JNK are thought to contribute
to inﬂammation and their arrest might therefore contribute to
withholding of TNF induced inﬂammation. Apoptotic death, on the
other hand, is believed to have anti-inﬂammatory consequences
[106], and its inhibition by pre-exposure to TNF or LPS might
therefore promote rather than weaken their proinﬂammatory
functions.
5.2.3. Induced intercellular interactions restricting TNF formation
and function
Within multicellular organisms, the response of individual cells
to an extracellular inducer can be modulated by products of the
responses of other cells to the same inducer. A major regulatory
process restricting both the formation and the function of TNF
in vivo through effects of mediators generated in remote cells is the
one activated by the hypothalamic–pituitary–adrenal axis [107].
TNF, like various other pro-inﬂammatory mediators, on reach-
ing high enough levels in the blood triggers pituitary release of
adrenocoticotropin, and this circulating hormone then triggers the
formation of corticosteroids in the adrenal gland and their release
from it. TNF also induces corticosteroid formation in the intestine
[108]. These corticosteroids block both TNF transcription and the
TNF-evoked induction of various proteins [45].
An additional molecule that restricts TNF formation in a man-
ner that involves multicellular interactions is cyclic AMP. Once
TNF is formed it stimulates prostaglandin generation through
the induction of cyclooxygenase-2 and the induction and acti-
vation of phospholipase A2 (e.g. [109]). Binding of the induced
prostaglandins to receptors on TNF-producing cells triggers the
generation of cyclic AMP, which effectively blocks TNF tran-
scription [110,111]. This inhibition is attenuated, however, by
TNF-mediated induction of cyclic AMP  phosphodiesterase [112]
6. TNF as a mediator of chronic self-perpetuating
inﬂammation
6.1. Phenomena
The view of TNF as an immune mediator whose formation
and function are always temporally restricted has been challenged
by studies demonstrating constitutive generation of TNF in cer-
tain chronically inﬂamed tissues [113–119]. Subsequent studies in
mice showed that chronic TNF generation imposed, among other
ways, by mutation of a regulatory region in the TNF transcript
[120] dictates pathological changes characteristic of chronic human
inﬂammatory diseases. Those ﬁndings, and the dramatic attenu-
ation of the activity of certain chronic inﬂammatory diseases in
humans injected with TNF-blocking agents, pointed to a causal role
for TNF in these diseases [121,122]. In many patients blocking of
TNF was found to have a durable curative effect that was main-
tained long after the inhibition was terminated [123], implying that
this causal role is preeminent.
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Some auto-inﬂammatory diseases are caused by inborn muta-
ions [124]. In contrast, there seems to be no such role for inborn
utations in the autoimmune diseases driven by TNF. Both the
hronic formation and the chronic action of TNF in these diseases
ust therefore be attributable to mechanisms that are dictated by
he normal genotype.
.2. Mechanisms
Studies of the impact of chronic exposure of ex vivo cul-
ured cells to TNF provided some clues to mechanisms that might
ontribute to the ability of this cytokine to exert prolonged proin-
ammatory effects (Figs. 1c and 2b), as detailed below.
.2.1. Prolonged exposure to TNF induces expression of genes
ith longer half-life
Short TNF stimuli induce genes whose transcription is rapid
nd whose half-life is short, resulting in cellular changes that are
wift but transient. Longer stimuli yield expression of genes that
re induced slowly, owing largely to a delay in splicing [125], and
hose half-life is long [126], resulting in cellular responses that
volve more slowly but are maintained for longer.
.2.2. Protracted activation of NF-B
Activation of NF-B in cells treated by TNF for different durations
as found to yield two distinct modes of response. Stimulation by
NF for up to a certain length of time activates NF-B for a ﬁxed
hort duration. With longer stimulation times this response is pro-
onged, and is maintained throughout the period of exposure to TNF
127].
The shift from transient to chronic activation is assisted by
edundancy at several mechanistic levels. There is redundancy of
he proximal mechanisms for NF-B activation, where different
hases in the process beneﬁt from linkages of branched and of
inear polyubiquitin chains, from phosphorylation of TFAF2, and
rom RIPK1-dependent and RIPK1-independent activation of NF-B
128,129].
There is also redundancy in the kinds of NF-B-induced proteins
hat bind to the NF-B dimers and block their functions. Phos-
horylation of the NF-B inhibitor IB by IKK2 is followed by
F-B-mediated activation of the IB gene, constituting a delayed
ype of feedback that yields an oscillating pattern of NF-B activa-
ion [130,131]. This oscillation is dampened by the more slowly
nduced IB and IB [130]. NF-B activation also yields genera-
ion of the NF-B proteins p100 and p105, which contain IB-like
nkyrin repeat moieties and can therefore also block the function
f the canonical NF-B complex [69–74]. However, one of the genes
ctivated by TNFR1 is the other, less frequently expressed TNF
eceptor, TNFR2 [132]. Triggering of TNFR2 by chronically applied
NF can activate the alternative NF-B pathway, in which prote-
lytic processing of p100 and p105 [73,74] can relieve inhibition
f the canonical pathway by these proteins. Activation of the alter-
ative NF-B pathway also yields RelB:p52 NF-B dimers, which
ave been shown to replace the canonical p65:p50 complexes at
he promoters of various TNF-induced genes in cells exposed to
NF for lengthy periods [133]. This late shift to NF-B dimers that
re insensitive to the effects of NF-B-induced IB proteins and of
ther inhibitors of the canonical NF-B pathway contributes to the
hronicity of the inﬂammatory response.
.2.3. Autocrine IFN-  ˇ signaling
Unlike TLR4 and some other pathogen-component receptorshose signaling initiates phosphorylation of the transcription fac-
or IRF3 and, as a consequence, activation of the interferon beta
IFN-) gene, the TNF receptors do not signal for IRF3 phospho-
ylation and therefore cannot activate the IFN- gene directly.ental Biology 50 (2016) 105–114 111
Nevertheless, prolonged TNF stimulation does result in low-level
induction of IFN- [134], probably as an outcome of its induction
of IRF1, another member of the IRF family that can activate the
interferon gene [135,136].
TNF induces epigenetic changes that result in increased acces-
sibility of the promoters of various inﬂammatory genes to
transcription factors [137]. In cells exposed over a long period to
TNF this increased accessibility is maintained for a while after TNF
removal, reﬂecting sustained gene remodeling that results in pro-
longed gene activation and ‘innate memory’ [138]. Some of the
genes manifesting such sustained activation are controlled by the
cooperative action of TNF-induced NF-B and IFN--induced Stat1
[139]. This autocrine function of IFN- in cells chronically exposed
to TNF probably accounts for the fact that many of the genes
induced in chronic inﬂammatory states to which TNF contributes
are characteristic of the interferon response [140].
6.2.4. Soluble TNF receptors: inhibitors or buffers?
When TNF receptors are shed in response to TNF or other
inducers, their cleavage occurs at the region that links their
ligand-binding motif to their transmembrane domains [141]. Such
cleavage thus results in the release of shed portions of the receptors
that maintain the ability to bind TNF. Substantial amounts of these
‘soluble TNF receptors’ accumulate at regions of chronic inﬂam-
mation [119,142]. When bound to these soluble receptors, TNF is
incapable of binding to the TNF receptors at the cell surface [143].
Initially, therefore, the shed soluble TNF receptors were thought to
serve as natural inhibitors of TNF function. More thorough charac-
terization revealed that binding of these soluble receptors to TNF
results not in irreversible inactivation of TNF but, quite the con-
trary, in stabilization of the trimeric (active) form of TNF and, since
the binding is reversible, the soluble receptors function rather as
‘buffering agents’ that modify the TNF effect from an abrupt spike
of strong stimulation to a mitigated but extended effect [144]. The
soluble TNF receptors probably also increase local concentrations
of TNF in closed body cavities by withholding its translocation
through their surrounding barriers.
6.2.5. What dictates the continuous generation of TNF in chronic
inﬂammatory diseases?
Unlike infectious diseases, in which inﬂammation is driven by
pathogen components, the inﬂammatory processes in autoimmune
diseases are believed to be perpetuated merely by interactions
among various host cells, and to occur through direct cell–cell
interactions and the various soluble mediators that these cells gen-
erate [145]. TNF-blocking agents can dictate sustained arrest of
both the effects and the formation of TNF in patients with such
diseases [123], implying that TNF generation in these diseases
is self-perpetuating. Self-perpetuation could occur through direct
TNF-mediated activation of the TNF gene. However, although the
TNF gene is indeed activated by TNF, this activation seems too tran-
sient to account for the unabated generation of TNF observed in
autoimmune diseases [126]. Other host-derived molecules, whose
nature is still unknown, are likely to trigger this self-induced gener-
ation. They seem to be produced, at least in part, by T lymphocytes
and NK cells, and to be presented to TNF-producing mononuclear
phagocytes through direct cell–cell contact [146–149].
6.3. Open questions
The apparent existence of molecular mechanisms that serve
speciﬁcally to allow TNF to act chronically suggests that this mode
of TNF function, despite its known pathological consequences, also
contributes beneﬁcially to immune defense. There are still large
gaps in our knowledge of these mechanisms. Little has been done to
explore the interrelationships between this mode of TNF action and
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he two others described in this essay, namely the hypersensitive
nrestricted response, and the restricted response characterizing
ndotoxin tolerance. In mesenchymal cells, whose activation by
NF appears to be pivotal for the initiation of chronic inﬂammatory
iseases to which TNF contributes [150], the induction of feedback
echanisms that restrict inﬂammatory responses seems to occur
ess effectively than in macrophages [137]. Still to be clariﬁed are
he extent of such heterogeneity among different cell types, the
dentity of the mechanisms that contribute to the heterogeneity,
nd the extent to which these mechanisms can be modulated by
xternal stimuli.
. Concluding remarks
As in Akira Kurosawa’s famous ﬁlm Rashomon,  so too in the study
f the highly pleiotropic function of TNF the notion of reality lies
n the eye of the beholder. Scientists tend to focus on the feature of
NF function that is highlighted by the particular TNF activity that
hey study. Each of the three modes of regulation of TNF function
ddressed in this essay has in turn become the focus of atten-
ion at different historical phases of the research on this cytokine.
espite differences in the levels of attention paid to them at dif-
erent times, all are likely to make important contributions both
o immune defense and to immune pathology. Moreover, given the
reat heterogeneity of the ways in which inﬂammation contributes
o defense, and the multiple means by which TNF affects cellu-
ar functions in inﬂammation, future studies are likely to reveal
dditional ways in which the nature, extent and duration of TNF
unction are controlled. The complexity of the subject is continuing
o unfold and substantial effort will be required over the coming
ears to address the open questions. In view of the key role of
he regulation of TNF function in health and especially in disease,
nvestment of such further effort is unquestionably worthwhile.
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